"In the phase II Tailored Postsurgical Therapy in Early-Stage NSCLC (TASTE) trial (IFCT-0801), reported in the Journal of Clinical Oncology, Wislez et al examined the feasibility of customized adjuvant treatment based on EGFR mutation status and expression of ERCC1 (excision repair cross-complementation group 1), a predictor of cisplatin response, in patients with non–small cell lung cancer (NSCLC). Although the trial met its primary endpoint of ≥ 80% of patients being able to start adjuvant chemotherapy within 2 months of surgery, a phase III trial of the customized approach was cancelled due to unreliability of ERCC1 immunohistochemical readouts."
Editor's note: This trial tested whether a particular molecular testing method could be used to decide which lung cancer patients might benefit from chemotherapy after surgery to keep the cancer from returning. While the results of the trial were promising, the third phase of the trial was canceled because of some unreliability of the molecular testing method. Another method called Pervenio, already performs a similar function.